Cytokinetics (CYTK) Projected to Post Earnings on Wednesday

Cytokinetics (NASDAQ:CYTK) is projected to release its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Cytokinetics to post earnings of ($1.59) per share and revenue of $6.05 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.22. The business had revenue of $66.77 million for the quarter, compared to analyst estimates of $1.95 million. The firm’s quarterly revenue was up 26727.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.31) earnings per share. On average, analysts expect Cytokinetics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Cytokinetics Trading Down 5.6%

NASDAQ:CYTK opened at $60.03 on Tuesday. The firm has a market capitalization of $7.18 billion, a price-to-earnings ratio of -11.77 and a beta of 0.67. Cytokinetics has a 1-year low of $29.31 and a 1-year high of $64.13. The business’s fifty day moving average price is $53.45 and its 200 day moving average price is $41.52.

Insider Buying and Selling

In other news, Director Edward M. Md Kaye sold 6,757 shares of the company’s stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $60.00, for a total transaction of $405,420.00. Following the completion of the sale, the director owned 9,778 shares in the company, valued at approximately $586,680. This represents a 40.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Fady Ibraham Malik sold 2,105 shares of the company’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $58.22, for a total value of $122,553.10. Following the sale, the executive vice president owned 140,610 shares of the company’s stock, valued at approximately $8,186,314.20. This trade represents a 1.47% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 54,688 shares of company stock worth $3,028,689. Insiders own 2.70% of the company’s stock.

Institutional Trading of Cytokinetics

Large investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its stake in Cytokinetics by 723.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares during the period. Cetera Investment Advisers boosted its stake in Cytokinetics by 12.4% during the 2nd quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 731 shares during the period. Shay Capital LLC boosted its stake in Cytokinetics by 48.5% during the 2nd quarter. Shay Capital LLC now owns 7,500 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 2,449 shares during the period. Gabelli Funds LLC boosted its stake in Cytokinetics by 29.4% during the 2nd quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 1,910 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in Cytokinetics by 29.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,086 shares of the biopharmaceutical company’s stock valued at $366,000 after purchasing an additional 2,551 shares during the period.

Analyst Ratings Changes

Several research firms recently weighed in on CYTK. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a research report on Monday, September 29th. B. Riley boosted their target price on Cytokinetics from $74.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 22nd. Barclays boosted their target price on Cytokinetics from $71.00 to $82.00 and gave the company an “overweight” rating in a research note on Monday, October 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics in a research note on Tuesday, October 21st. Finally, Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a research note on Tuesday, September 2nd. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $76.64.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.